The management of brain metastases in non-small cell lung cancer

Frontiers in Oncology

Volumn 4 JUL, Issue , 2014, Pages

  Owen, Scott ^a   Souhami, Luis ^a  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AFATINIB; CISPLATIN; CRIZOTINIB; DACOMITINIB; DEXAMETHASONE; DOCETAXEL; ERLOTINIB; GEFITINIB; MEMANTINE; PEMETREXED; ANAPLASTIC LYMPHOMA KINASE; EPIDERMAL GROWTH FACTOR RECEPTOR;

BLOOD BRAIN BARRIER; BRAIN METASTASIS; CANCER PROGNOSIS; CANCER SURVIVAL; COGNITION; COMPUTER ASSISTED TOMOGRAPHY; FOLLOW UP; HUMAN; KARNOFSKY PERFORMANCE STATUS; LUNG NON SMALL CELL CANCER; MULTICENTER STUDY (TOPIC); NUCLEAR MAGNETIC RESONANCE IMAGING; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PROGRESSION FREE SURVIVAL; QUALITY OF LIFE; RADIATION DOSE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SCORING SYSTEM; SHORT SURVEY; STEREOTACTIC RADIOSURGERY; SYSTEMATIC REVIEW (TOPIC); TUMOR RECURRENCE; CANCER RADIOTHERAPY; CANCER SURGERY; GENE MUTATION; INTRACRANIAL PRESSURE; MOLECULARLY TARGETED THERAPY; NON SMALL CELL LUNG CANCER; SHORT TERM MEMORY; WHOLE BRAIN RADIATION THERAPY;

EID: 84907926192     PISSN: None     EISSN: 2234943X     Source Type: Journal    
DOI: 10.3389/fonc.2014.00248     Document Type: Short Survey

References (60)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90. Epub 2011/02/08. doi: 10.3322/caac.20107. PubMed PMID: 21296855.
2. Schuette W. Treatment of brain metastases from lung cancer: chemotherapy. Lung Cancer. 2004;45 Suppl 2:S253-7. Epub 2004/11/24. doi: 10.1016/j.lungcan.2004.07.967. PubMed PMID: 15552807.
3. Langer CJ, Mehta MP. Current management of brain metastases, with a focus on systemic options. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2005;23(25):6207-19. Epub 2005/09/02. doi: 10.1200/jco.2005.03.145. PubMed PMID: 16135488.
4. Lagerwaard FJ, Levendag PC, Nowak PJ, Eijkenboom WM, Hanssens PE, Schmitz PI. Identification of prognostic factors in patients with brain metastases: a review of 1292 patients. Int J Radiat Oncol Biol Phys. 1999;43(4):795-803. Epub 1999/03/31. PubMed PMID: 10098435.
5. Lind JS, Lagerwaard FJ, Smit EF, Postmus PE, Slotman BJ, Senan S. Time for reappraisal of extracranial treatment options? Synchronous brain metastases from nonsmall cell lung cancer. Cancer. 2011;117(3):597-605. Epub 2010/09/28. doi: 10.1002/cncr.25416. PubMed PMID: 20872880.
6. Jamal-Hanjani M, Spicer J. Epidermal growth factor receptor tyrosine kinase inhibitors in the treatment of epidermal growth factor receptor-mutant non-small cell lung cancer metastatic to the brain. Clin Cancer Res. 2012;18(4):938-44. Epub 2011/12/15. doi: 10.1158/1078-0432.ccr-11-2529. PubMed PMID: 22167408.
7. Gaspar L, Scott C, Rotman M, Asbell S, Phillips T, Wasserman T, et al. Recursive partitioning analysis (RPA) of prognostic factors in three Radiation Therapy Oncology Group (RTOG) brain metastases trials. Int J Radiat Oncol Biol Phys. 1997;37(4):745-51. Epub 1997/03/01. PubMed PMID: 9128946.
8. Weltman E, Salvajoli JV, Brandt RA, de Morais Hanriot R, Prisco FE, Cruz JC, et al. Radiosurgery for brain metastases: a score index for predicting prognosis. Int J Radiat Oncol Biol Phys. 2000;46(5):1155-61. Epub 2000/03/22. PubMed PMID: 10725626.
9. Lorenzoni J, Devriendt D, Massager N, David P, Ruiz S, Vanderlinden B, et al. Radiosurgery for treatment of brain metastases: estimation of patient eligibility using three stratification systems. Int J Radiat Oncol Biol Phys. 2004;60(1):218-24. Epub 2004/09/01. doi: 10.1016/j.ijrobp.2004.02.017. PubMed PMID: 15337559.
10. Sperduto PW, Berkey B, Gaspar LE, Mehta M, Curran W. A new prognostic index and comparison to three other indices for patients with brain metastases: an analysis of 1,960 patients in the RTOG database. Int J Radiat Oncol Biol Phys. 2008;70(2):510-4. Epub 2007/10/13. doi: 10.1016/j.ijrobp.2007.06.074. PubMed PMID: 17931798.
11. Rades D, Dunst J, Schild SE. A new scoring system to predicting the survival of patients treated with whole-brain radiotherapy for brain metastases. Strahlenther Onkol. 2008;184(5):251-5. Epub 2008/04/23. doi: 10.1007/s00066-008-1831-5. PubMed PMID: 18427755.
12. Viani GA, da Silva LG, Stefano EJ. Prognostic indexes for brain metastases: which is the most powerful? Int J Radiat Oncol Biol Phys. 2012;83(3):e325-30. Epub 2012/05/29. doi: 10.1016/j.ijrobp.2011.12.082. PubMed PMID: 22633551.
13. Coate LE, John T, Tsao M-S, Shepherd FA. Molecular predictive and prognostic markers in non-small-cell lung cancer. The Lancet Oncology. 2009;10(10):1001-10.
14. Zhu CQ, Ding K, Strumpf D, Weir BA, Meyerson M, Pennell N, et al. Prognostic and predictive gene signature for adjuvant chemotherapy in resected non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2010;28(29):4417-24. Epub 2010/09/09. doi: 10.1200/jco.2009.26.4325. PubMed PMID: 20823422; PubMed Central PMCID: PMCPmc2988634.
15. Temel JS, Greer JA, Muzikansky A, Gallagher ER, Admane S, Jackson VA, et al. Early Palliative Care for Patients with Metastatic Non-Small-Cell Lung Cancer. New England Journal of Medicine. 2010;363(8):733-42. doi: doi:10.1056/NEJMoa1000678. PubMed PMID: 20818875.
16. Ryken TC, McDermott M, Robinson PD, Ammirati M, Andrews DW, Asher AL, et al. The role of steroids in the management of brain metastases: a systematic review and evidence-based clinical practice guideline. J Neurooncol. 2010;96(1):103-14. Epub 2009/12/04. doi: 10.1007/s11060-009-0057-4. PubMed PMID: 19957014; PubMed Central PMCID: PMCPmc2808527.
17. Patchell RA, Tibbs PA, Walsh JW, Dempsey RJ, Maruyama Y, Kryscio RJ, et al. A randomized trial of surgery in the treatment of single metastases to the brain. N Engl J Med. 1990;322(8):494-500. Epub 1990/02/22. doi: 10.1056/nejm199002223220802. PubMed PMID: 2405271.
18. Vecht CJ, Haaxma-Reiche H, Noordijk EM, Padberg GW, Voormolen JH, Hoekstra FH, et al. Treatment of single brain metastasis: radiotherapy alone or combined with neurosurgery? Ann Neurol. 1993;33(6):583-90. Epub 1993/06/01. doi: 10.1002/ana.410330605. PubMed PMID: 8498838.
19. Mintz AH, Kestle J, Rathbone MP, Gaspar L, Hugenholtz H, Fisher B, et al. A randomized trial to assess the efficacy of surgery in addition to radiotherapy in patients with a single cerebral metastasis. Cancer. 1996;78(7):1470-6. Epub 1996/10/01. PubMed PMID: 8839553.
20. Patchell RA, Tibbs PA, Regine WF, Dempsey RJ, Mohiuddin M, Kryscio RJ, et al. Postoperative radiotherapy in the treatment of single metastases to the brain: a randomized trial. Jama. 1998;280(17):1485-9. Epub 1998/11/11. PubMed PMID: 9809728.
21. Khuntia D, Brown P, Li J, Mehta MP. Whole-brain radiotherapy in the management of brain metastasis. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2006;24(8):1295-304. Epub 2006/03/10. doi: 10.1200/jco.2005.04.6185. PubMed PMID: 16525185.
22. Borgelt B, Gelber R, Kramer S, Brady LW, Chang CH, Davis LW, et al. The palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. International journal of radiation oncology, biology, physics. 1980;6(1):1-9. Epub 1980/01/01. PubMed PMID: 6154024.
23. Borgelt B, Gelber R, Larson M, Hendrickson F, Griffin T, Roth R. Ultra-rapid high dose irradiation schedules for the palliation of brain metastases: final results of the first two studies by the Radiation Therapy Oncology Group. International journal of radiation oncology, biology, physics. 1981;7(12):1633-8. Epub 1981/12/01. PubMed PMID: 6174490.
24. Kurtz JM, Gelber R, Brady LW, Carella RJ, Cooper JS. The palliation of brain metastases in a favorable patient population: a randomized clinical trial by the Radiation Therapy Oncology Group. International journal of radiation oncology, biology, physics. 1981;7(7):891-5. Epub 1981/07/01. PubMed PMID: 6171553.
25. Harwood AR, Simson WJ. Radiation therapy of cerebral metastases: a randomized prospective clinical trial. International journal of radiation oncology, biology, physics. 1977;2(11-12):1091-4. Epub 1977/11/01. PubMed PMID: 74375.
26. Chatani M, Matayoshi Y, Masaki N, Inoue T. Radiation therapy for brain metastases from lung carcinoma. Prospective randomized trial according to the level of lactate dehydrogenase. Strahlentherapie und Onkologie: Organ der Deutschen Rontgengesellschaft [et al]. 1994;170(3):155-61. Epub 1994/03/01. PubMed PMID: 8160096.
27. Haie-Meder C, Pellae-Cosset B, Laplanche A, Lagrange JL, Tuchais C, Nogues C, et al. Results of a randomized clinical trial comparing two radiation schedules in the palliative treatment of brain metastases. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 1993;26(2):111-6. Epub 1993/02/01. PubMed PMID: 7681997.
28. Meyers CA, Smith JA, Bezjak A, Mehta MP, Liebmann J, Illidge T, et al. Neurocognitive function and progression in patients with brain metastases treated with whole-brain radiation and motexafin gadolinium: results of a randomized phase III trial. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2004;22(1):157-65. Epub 2004/01/01. doi: 10.1200/jco.2004.05.128. PubMed PMID: 14701778.
29. McDuff SG, Taich ZJ, Lawson JD, Sanghvi P, Wong ET, Barker FG, 2nd, et al. Neurocognitive assessment following whole brain radiation therapy and radiosurgery for patients with cerebral metastases. Journal of neurology, neurosurgery, and psychiatry. 2013;84(12):1384-91. Epub 2013/05/30. doi: 10.1136/jnnp-2013-305166. PubMed PMID: 23715918.
30. Brown PD, Pugh S, Laack NN, Wefel JS, Khuntia D, Meyers C, et al. Memantine for the prevention of cognitive dysfunction in patients receiving whole-brain radiotherapy: a randomized, double-blind, placebocontrolled trial. Neuro Oncol. 2013;15(10):1429-37. Epub 2013/08/21. doi: 10.1093/neuonc/not114. PubMed PMID: 23956241; PubMed Central PMCID: PMCPmc3779047.
31. Gondi V, Tome WA, Marsh J, Struck A, Ghia A, Turian JV, et al. Estimated risk of perihippocampal disease progression after hippocampal avoidance during whole-brain radiotherapy: Safety profile for RTOG 0933. Radiotherapy and oncology: journal of the European Society for Therapeutic Radiology and Oncology. 2010;95(3):327-31.
32. Andrews DW, Scott CB, Sperduto PW, Flanders AE, Gaspar LE, Schell MC, et al. Whole brain radiation therapy with or without stereotactic radiosurgery boost for patients with one to three brain metastases: phase III results of the RTOG 9508 randomised trial. Lancet. 2004;363(9422):1665-72. Epub 2004/05/26. doi: 10.1016/s0140-6736(04)16250-8. PubMed PMID: 15158627.
33. Chougule P, Burton-Williams M, Saris M. Randomized treatment of brain metastases with gamma knife radiosurgery, whole brain radiotherapy or both. International journal of radiation oncology, biology, physics. 2000;48:114.
34. Aoyama H, Shirato H, Tago M, Nakagawa K, Toyoda T, Hatano K, et al. Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: a randomized controlled trial. Jama. 2006;295(21):2483-91. Epub 2006/06/08. doi: 10.1001/jama.295.21.2483. PubMed PMID: 16757720.
35. Chang EL, Wefel JS, Hess KR, Allen PK, Lang FF, Kornguth DG, et al. Neurocognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: a randomised controlled trial. Lancet Oncol. 2009;10(11):1037-44. Epub 2009/10/06. doi: 10.1016/s1470-2045(09)70263-3. PubMed PMID: 19801201.
36. Kocher M, Soffietti R, Abacioglu U, Villa S, Fauchon F, Baumert BG, et al. Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: results of the EORTC 22952-26001 study. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2011;29(2):134-41. Epub 2010/11/03. doi: 10.1200/jco.2010.30.1655. PubMed PMID: 21041710; PubMed Central PMCID: PMCPmc3058272.
37. Walbert T, Gilbert MR. The role of chemotherapy in the treatment of patients with brain metastases from solid tumors. Int J Clin Oncol. 2009;14(4):299-306. Epub 2009/08/26. doi: 10.1007/s10147-009-0916-1. PubMed PMID: 19705239.
38. van den Bent MJ. The role of chemotherapy in brain metastases. Eur J Cancer. 2003;39(15):2114-20. Epub 2003/10/03. PubMed PMID: 14522368.
39. Gerstner ER, Fine RL. Increased permeability of the blood-brain barrier to chemotherapy in metastatic brain tumors: establishing a treatment paradigm. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2007;25(16):2306-12. Epub 2007/06/01. doi: 10.1200/jco.2006.10.0677. PubMed PMID: 17538177.
40. Barlesi F, Gervais R, Lena H, Hureaux J, Berard H, Paillotin D, et al. Pemetrexed and cisplatin as first-line chemotherapy for advanced non-small-cell lung cancer (NSCLC) with asymptomatic inoperable brain metastases: a multicenter phase II trial (GFPC 07-01). Ann Oncol. 2011;22(11):2466-70. Epub 2011/02/16. doi: 10.1093/annonc/mdr003. PubMed PMID: 21321089.
41. Dinglin XX, Huang Y, Liu H, Zeng YD, Hou X, Chen LK. Pemetrexed and cisplatin combination with concurrent whole brain radiotherapy in patients with brain metastases of lung adenocarcinoma: a single-arm phase II clinical trial. J Neurooncol. 2013;112(3):461-6. Epub 2013/02/20. doi: 10.1007/s11060-013-1079-5. PubMed PMID: 23420398.
42. Ettinger DS, Akerley W, Borghaei H, Chang AC, Cheney RT, Chirieac LR, et al. Non-small cell lung cancer, version 2.2013. J Natl Compr Canc Netw. 2013;11(6):645-53; quiz 53. Epub 2013/06/08. PubMed PMID: 23744864.
43. Kohler J, Schuler M. Afatinib, erlotinib and gefitinib in the first-line therapy of EGFR mutation-positive lung adenocarcinoma: a review. Onkologie. 2013;36(9):510-8. Epub 2013/09/21. doi: 10.1159/000354627. PubMed PMID: 24051929.
44. Mok TS, Wu YL, Thongprasert S, Yang CH, Chu DT, Saijo N, et al. Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. N Engl J Med. 2009;361(10):947-57. Epub 2009/08/21. doi: 10.1056/NEJMoa0810699. PubMed PMID: 19692680.
45. Rosell R, Carcereny E, Gervais R, Vergnenegre A, Massuti B, Felip E, et al. Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-smallcell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2012;13(3):239-46. Epub 2012/01/31. doi: 10.1016/s1470-2045(11)70393-x. PubMed PMID: 22285168.
46. Sequist LV, Yang JC, Yamamoto N, O'Byrne K, Hirsh V, Mok T, et al. Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(27):3327-34. Epub 2013/07/03. doi: 10.1200/jco.2012.44.2806. PubMed PMID: 23816960.
47. Yang JC, Hirsh V, Schuler M, Yamamoto N, O'Byrne KJ, Mok TS, et al. Symptom control and quality of life in LUX-Lung 3: a phase III study of afatinib or cisplatin/pemetrexed in patients with advanced lung adenocarcinoma with EGFR mutations. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2013;31(27):3342-50. Epub 2013/07/03. doi: 10.1200/jco.2012.46.1764. PubMed PMID: 23816967.
48. Ramalingam SS, Blackhall F, Krzakowski M, Barrios CH, Park K, Bover I, et al. Randomized phase II study of dacomitinib (PF-00299804), an irreversible pan-human epidermal growth factor receptor inhibitor, versus erlotinib in patients with advanced non-small-cell lung cancer. Journal of clinical oncology: official journal of the American Society of Clinical Oncology. 2012;30(27):3337-44. Epub 2012/07/04. doi: 10.1200/jco.2011.40.9433. PubMed PMID: 22753918.
49. Shaw AT, Kim DW, Nakagawa K, Seto T, Crino L, Ahn MJ, et al. Crizotinib versus chemotherapy in advanced ALK-positive lung cancer. N Engl J Med. 2013;368(25):2385-94. Epub 2013/06/04. doi: 10.1056/NEJMoa1214886. PubMed PMID: 23724913.
50. Shaw AT, Kim DW, Mehra R, Tan DS, Felip E, Chow LQ, et al. Ceritinib in ALK-rearranged non-small-cell lung cancer. N Engl J Med. 2014;370(13):1189-97. Epub 2014/03/29. doi: 10.1056/NEJMoa1311107. PubMed PMID: 24670165.
51. Luo D, Ye X, Hu Z, Peng K, Song Y, Yin X, et al. EGFR mutation status and its impact on survival of Chinese non-small cell lung cancer patients with brain metastases. Tumour Biol. 2014;35(3):2437-44. Epub 2013/11/08. doi: 10.1007/s13277-013-1323-9. PubMed PMID: 24197981.
52. Eichler AF, Kahle KT, Wang DL, Joshi VA, Willers H, Engelman JA, et al. EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer. Neuro Oncol. 2010;12(11):1193-9. Epub 2010/07/16. doi: 10.1093/neuonc/noq076. PubMed PMID: 20627894; PubMed Central PMCID: PMCPmc3098020.
53. Oskan F, Ganswindt U, Schwarz SB, Manapov F, Belka C, Niyazi M. Hippocampus sparing in whole-brain radiotherapy. Strahlenther Onkol. 2014;190(4):337-41. doi: 10.1007/s00066-013-0518-8.
54. O'Flaherty JD, Gray S, Richard D, Fennell D, O'Leary JJ, Blackhall FH, et al. Circulating tumour cells, their role in metastasis and their clinical utility in lung cancer. Lung Cancer. 2012;76(1):19-25. doi: http://dx.doi.org/10.1016/j.lungcan.2011.10.018.
55. Sundar R, Soong R, Cho B-C, Brahmer JR, Soo RA. Immunotherapy in the treatment of non-small cell lung cancer. Lung Cancer. (0). doi: http://dx.doi.org/10.1016/j.lungcan.2014.05.005.
56. Shepherd FAMD, Douillard J-YMDP, Blumenschein GRJMD. Immunotherapy for Non-small Cell Lung Cancer: Novel Approaches to Improve Patient Outcome. Journal of Thoracic Oncology. 2011;6(10):1763-73.
57. Eldredge HB, Denittis A, Duhadaway JB, Chernick M, Metz R, Prendergast GC. CONCURRENT WHOLE BRAIN RADIOTHERAPY AND SHORT-COURSE CHLOROQUINE IN PATIENTS WITH BRAIN METASTASES: A PILOT TRIAL. Journal of radiation oncology. 2013;2(3). Epub 2013/11/05. doi: 10.1007/s13566-013-0111-x. PubMed PMID: 24187608; PubMed Central PMCID: PMCPmc3810973.
58. Garon EB, Christofk HR, Hosmer W, Britten CD, Bahng A, Crabtree MJ, et al. Dichloroacetate should be considered with platinum-based chemotherapy in hypoxic tumors rather than as a single agent in advanced nonsmall cell lung cancer. Journal of cancer research and clinical oncology. 2014;140(3):443-52. Epub 2014/01/21. doi: 10.1007/s00432-014-1583-9. PubMed PMID: 24442098; PubMed Central PMCID: PMCPmc3939783.
59. Blumenschein GR, Jr. Developmental antiangiogenic agents for the treatment of non-small cell lung cancer (NSCLC). Investigational new drugs. 2012;30(4):1802-11. Epub 2011/10/12. doi: 10.1007/s10637-011-9750-1. PubMed PMID: 21987350.
60. Berge EM, Doebele RC. Targeted therapies in non-small cell lung cancer: emerging oncogene targets following the success of epidermal growth factor receptor. Seminars in oncology. 2014;41(1):110-25. Epub 2014/02/26. doi: 10.1053/j.seminoncol.2013.12.006. PubMed PMID: 24565585.